Boston, Massachusetts–(Newsfile Corp. – August 6, 2021) – The Thornton Law Firm alerts investors that it is investigating Annovis Bio, Inc. (NYSE American: ANVS) for potential securities violations. Investors who currently own shares or options of ANVS may contact the Thornton Law Firm’s investor protection team by visiting www.tenlaw.com/cases/Annovis for more information. Investors may also email [email protected] or call 617-531-3917.

FOR MORE INFORMATION: www.tenlaw.com/cases/Annovis

On July 28, 2021, after the market closed, Annovis reported clinical trial data for Posiphen that failed to show statistical significance in treating Alzheimer’s and Parkinson’s Disease patients relative to a placebo. Following this news, Annovis’ stock price declined $65.94 per share or over 60%. The investigation seeks to determine if Annovis misled investors about Posiphen’s efficacy in treating patients with Alzheimer’s and Parkinson’s Diseases.

FOR MORE INFORMATION: www.tenlaw.com/cases/Annovis

Thornton Law Firm’s securities attorneys are highly experienced in representing investors in recovering damages caused by violations of the securities laws. Its attorneys have established track records litigating securities cases in courts throughout the country and recovering losses on behalf of investors. This may be considered Attorney Advertising in some jurisdictions. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

CONTACT:
Thornton Law Firm LLP
1 Lincoln Street
State Street Financial Center
Boston, MA 02111
www.tenlaw.com/cases/Annovis

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/92311